Replies to post #251487 on Biotech Values

[Biowatch]

As you stated:

If the (placebo-adjusted) OSA benefit is seen early in the two one-year trials—i.e. before patients have lost a significant amount of weight—we may surmise that Zepbound is having a direct effect on symptoms, and people will want to know what the MoA is. On the other hand, if the OSA benefit kicks in mostly during the latter months of these trials, we may presume that the OSA benefit stems, at least in large part, from the weight loss.

I’m not sure what MoA would cause a reduction in sleep apnea aside from weight loss.

However, sleep apnea has deleterious effects on health, so reducing its impact is a good thing.